GMED

Globus Medical, Inc.

MedTech Long '25: Aging-Driven Procedures & Care

Loading…

Overview

Globus Medical makes the hardware and guidance tools surgeons use to fix spines, broken bones, and chronic nerve pain. Think of it as selling the “screws, rods,

Globus Medical makes the hardware and guidance tools surgeons use to fix spines, broken bones, and chronic nerve pain. Think of it as selling the “screws, rods, scaffolding, and GPS systems” for surgery. About 90%+ of revenue comes from implants (spine, trauma, joints, biologics, neuromodulation), and 5–10% from robotics/navigation. They sell mainly to hospitals, surgery centers, and spine/orthopedic surgeons; no single customer dominates sales.

What They Do (Plain English & Analogies): Think of Globus as the company that makes the “nuts, bolts, scaffolding and GPS systems” for spine and orthopedic surgeons. It designs metal implants, plates, screws and rods that hold bones and spines in place, plus surgical robots and navigation systems that guide the surgeon like Google Maps in the operating room. TradingView+3Globus Medical+3Globus Medical+3
Very Brief History: Founded in 2003 by engineer-entrepreneur David Paul as a fast-moving spine-implant boutique; IPO'd in 2012 and grew by taking share from bigger med-techs in spine. In 2023 it bought NuVasive (another spine specialist), and in 2025 agreed to acquire Nevro (chronic-pain nerve stimulators), becoming a broader musculoskeletal and neuromodulation platform. GlobeNewswire+4Wikipedia+4GlobeNewswire+4
"Street Stereotype": Seen as the “innovative spine/robotics pure-play that turned into a consolidator.” Known for moving quickly, winning surgeon converts, and pushing robotic spine surgery. Post-NuVasive and Nevro, the stereotype is: high-growth spine + trauma + robotics story with real upside, but now also an integration and margin-management story rather than a simple clean growth story. Investors+4Globus Medical+4GlobeNewswire+4
Subsidiaries On Linked In*: Not exhaustive, but examples of entities that appear as distinct organizations on LinkedIn and are effectively under the Globus umbrella: • Globus Medical, Inc. (parent) LinkedIn • Globus Medical S.R.L. (Italy) LinkedIn • NuVasive, Inc. (spine implants & procedures; now owned by Globus) LinkedIn+2Wikipedia+2 • NuVasive Clinical Services / NCS (intra-operative neuromonitoring services) LinkedIn • NuVasive Specialized Orthopedics (limb-lengthening and complex reconstruction) LinkedIn+1 • Nevro Corp. (spinal cord stimulators for chronic pain – being acquired and already consolidated in 2025 results) SEC+1
Customer Sectors & Example Clients: Direct customers are hospitals, surgery centers, and orthopedic / neurosurgeons doing spine, trauma, joint and pain procedures. SEC+2TradingView+2 The company doesn't list “top clients,” but likely heavy users are large U.S. hospital systems and spine centers that do lots of complex spine/trauma work and buy advanced robots – for example big academic systems (e.g., Mayo Clinic, Cleveland Clinic, Hospital for Special Surgery) and large hospital chains (e.g., HCA). These names are illustrative, not disclosed, based on the type of work they do and their use of similar technologies.
New Customers / Segments They'Re Targeting: They're pushing beyond core spine surgeons into: • Trauma and limb-reconstruction surgeons (ANTHEM trauma portfolio, limb-lengthening products). Globus Medical+2Globus Medical+2 • Joint reconstruction surgeons (hips, knees, extremities). Globus Medical+1 • Pain specialists and neurosurgeons implanting spinal cord stimulators via Nevro. SEC+1 • Smaller and community hospitals and ambulatory surgery centers that want robotics/navigation but couldn't justify a big-iron system before. Globus Medical+2Globus Medical+2
How Key Themes May Help/Hurt: Main rivals are big med-techs in spine/orthopedics and neuromodulation: Medtronic, Johnson & Johnson's DePuy Synthes, Stryker, Zimmer Biomet for spine/trauma/joint implants; and Boston Scientific, Abbott, Medtronic in spinal cord stimulation. TradingView+2Wikipedia+2 GMED tries to differentiate by: • Being more focused and faster-moving in spine/trauma vs diversified conglomerates. • Pairing implants with its own robotic/navigation platform (ExcelsiusGPS) as an integrated “ecosystem.” Globus Medical+1 • Offering less-invasive lateral procedures (from NuVasive's XLIF/X360 portfolios) and now neuromodulation, giving surgeons a full menu of options. NuVasive+2NuVasive+2

3 Main Long-Term Bull Details

Helps: An aging population means more worn-out spines, arthritic joints and fragile bones → more demand for spine fusions, fracture fixation and joint replacements, and for chronic-pain devices like spinal cord stimulators. GMED sells the hardware and robots behind those procedures. Globus Medical+2Globus Medical+2 Hurts: Aging also pushes payers (Medicare and insurers) to squeeze prices and favor lower-cost settings. That can pressure device prices and capital budgets for robots, even as procedure volumes rise. TradingView+1

3 Main Long-Term Bear Details

Share gains + bigger portfolio: After acquiring NuVasive, Globus is one of the scale leaders in spine with trauma and joint reconstruction as additional growth engines. It has been growing U.S. spine faster than the market, and full-year 2024 sales rose ~61% (helped by the merger) to ~$2.5B. Globus Medical Investors+3GlobeNewswire+3GlobeNewswire+3 2. Robotics & enabling tech flywheel: ExcelsiusGPS (robotic navigation) plus imaging and software can drive “razor-and-blades” economics: one robot leads to years of implant pull-through. Management is explicitly trying to make robotic-assisted spine surgery the standard of care. TradingView+3Globus Medical+3Globus Medical+3 3. Nevro/neuromodulation optionality: Adding Nevro's spinal cord stimulators opens a large chronic-pain market and adds a second high-margin platform. Q3-25 results already show Nevro's revenue and improving margins, and the deal is expected to be accretive in 2025, earlier than initially signaled. Investors+3SEC+3BioSpace+3

Recent Performance & What The Market'S Focused On: 1. Integration & execution risk: Rolling together Globus, NuVasive and Nevro is complex—different cultures, sales forces and IT systems. If they stumble on integration, surgeon service could suffer, synergies may disappoint, and margins could stay below investors' hopes. GlobeNewswire+3Globus Medical Investors+3TradingView+3 2. Heavy competition & pricing pressure: Spine and neuromod are brutally competitive, with Medtronic, Stryker, DePuy, Boston Scientific, Abbott and others all pushing robots, lateral surgery and stimulators. Hospitals and payers constantly press for discounts, and “innovative” products often get commoditized over time. SEC+4TradingView+4Globus Medical+4 3. Exposure to elective procedure cycles & capital spending: Many of its products are used in semi-elective surgeries. Recessions, pandemics or hospital staffing shortages can delay procedures and postpone robot purchases, which hits both implant and enabling-tech sales. GlobeNewswire+2GlobeNewswire+2

Bull / Bear Details

Globus is evolving from a fast-growing spine specialist into a broader musculoskeletal and pain platform (spine, trauma, joints, neuromodulation) with rising ma

Thesis

Globus is evolving from a fast-growing spine specialist into a broader musculoskeletal and pain platform (spine, trauma, joints, neuromodulation) with rising margins and strong free cash flow. The updated thesis hinges on sustaining above-market U.S. spine growth, scaling trauma/joints, and successfully integrating Nevro while managing lumpier robotics capital sales.

Bull case

U.S. spine is growing high single digits and gaining share, supported by 30+ weeks of consecutive growth, strong competitive rep hiring, and broad portfolio strength (not just one product).
Trauma is inflecting with portfolio breadth now ~80% of key competitors, enabling bids for primary vendor contracts at major trauma centers; joints and EFlex robot add longer-term optionality.
Nevro is already EBITDA and free-cash-flow positive, brought forward to EPS-accretive in 2025, giving GMED a scalable neuromodulation platform and IP that can be leveraged into new pain indications.

Bear case

Integration risk across NuVasive and Nevro remains high; cultural, systems, and salesforce missteps could slow growth, delay synergies, or pressure service levels to surgeons.
Enabling Technologies (robots/navigation) saw a sharp revenue decline as deals shift from upfront cash to leases/pay-per-use and hospitals re-prioritize capex; this could keep reported growth volatile and make modeling harder.
Spine and neuromodulation are intensely competitive and subject to pricing and reimbursement pressure; if payers or hospitals push harder on price or favor incumbents, it could cap GMED's growth and margin expansion despite good execution.

Bull / Bear Case

Bear Case: Growth now depends on executing three complex stories at once: integrating NuVasive and Nevro, reigniting lumpy robot/capital sales, and fixing international supply. Hospitals are scrutinizing capex, robotics deals are shifting to leases (pressuring reported revenue), and pricing/reimbursement pressure in spine and pain could cap margins. The stock already trades at a premium to the market and assumes continued flawless execution.
Bull Case: Globus is emerging as a top-tier spine/trauma/pain platform: U.S. spine is gaining share, trauma is scaling, and Nevro is already profitable and cash-generative. Margin/FCF trajectory is strong, balance sheet is clean, and robotics + neuromodulation give long runway optionality. Valuation, while not cheap, is below its own historical multiples and some peers.
More Compelling & Why: I'd lean slightly toward the bull case: you're getting a high-quality, above-market grower with strengthening margins and FCF at a valuation that's materially lower than its own history and below some large-cap med-tech peers, while still reflecting integration/robot risk. Risk/reward looks reasonably balanced but mildly favorable rather than a screaming bargain.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
Intra-quarter guidance update or pre-announcement (8-K / press release)	Direct read on whether Q4 / full-year sales and EPS are tracking above or below the raised guide from Q3.	Any 8-K or press release that changes 2025 revenue guide ($2.86–2.90B) or EPS guide ($3.75–3.85).	Bullish: Raise revenue or EPS above the current high end, or narrow the range upward. Bearish: Cut guidance below the low end or signal “toward the low end of range” with weak qualitative commentary.	Company IR site (press releases), SEC EDGAR (8-K), Bloomberg/FactSet news alerts.	Google Alerts/News for “Globus Medical guidance”; your proprietary workforce data for sudden hiring freezes/layoffs.	Street estimate revisions (FactSet, Bloomberg, Visible Alpha); earnings-pre-release screens; sell-side models.
Evidence on U.S. Spine growth and share (peer earnings + commentary)	U.S. Spine is the core profit engine; management is targeting stable high-single-digit, above-market growth. A clear slowdown vs peers would challenge the thesis.	Commentary and segment data from Medtronic, J&J/DePuy, Stryker, Zimmer Biomet on U.S. spine volumes and share; any GMED comment at conferences suggesting “modest” or “below market” growth.	Bullish: Peers describe solid U.S. spine volume; GMED (at conferences) reiterates “high-single-digit or better” U.S. spine growth and continued rep conversions. Bearish: Peers talk about slowing procedures or aggressive discounting, and GMED hints at “mid-single-digit” or “below market” U.S. spine growth.	Peer and GMED transcripts on company IR sites / Seeking Alpha; J.P. Morgan HC conf, NASS/AAOS presentations; sell-side notes.	Google Trends for spine surgery terms; LinkedIn job postings for “Globus Medical spine sales”; your workforce data for rep hiring vs peers.	Claims / procedure-volume data (IQVIA, Syntellis, PINC AI); hospital purchasing datasets (e.g., IQVIA device trackers); med-tech alt data vendors tracking OR procedure mix.
Enabling Technologies (robotics/navigation) demand – deals, leases, new clearances	Robots & navigation drive a long “razor/razor-blade” implant pull-through; last quarter's −27% YoY was the main weak spot.	Any disclosure of large Excelsius placements, expanded hospital system deals, or further commentary that deals are slipping / pivoting heavily to leases; any major new 510(k) clearance for Excelsius platform.	Bullish: News of multi-robot system deals, commentary that enabling-tech revenue is stabilizing or returning to growth, or clear adoption of newer offerings like ExcelsiusXR. Bearish: More comments about delayed or cancelled deals, or another year of double-digit % declines implied for robots.	GMED press releases; FDA 510(k) database for new Excelsius clearances; med-tech news sites (MassDevice, MedTech Dive).	Google Trends for “ExcelsiusGPS” / “Globus robot”; conference chatter on X / Reddit (e.g., r/medicine, r/orthopaedics) about spine robots; LinkedIn photos/posts from hospitals announcing new robots.	Capital equipment trackers; hospital capex / construction datasets; OR equipment utilization feeds; claims-based data on robot-assisted spine procedures.
Nevro (neuromodulation) performance: margins & cash flow	The Nevro deal is a key leg of the platform story; market was surprised by how quickly it turned profitable. Backtracking would hurt the “platform & margin” narrative.	Any intra-quarter color (conferences, 8-Ks) on Nevro EBITDA margin, cash generation, or restructuring costs; any major product issues, recall, or payor pushback on spinal cord stimulation reimbursement.	Bullish: Further commentary that Nevro margins are improving (e.g., toward high-teens / 20% EBITDA) and free-cash-flow positive, plus signs of rep expansion and surgeon wins. Bearish: New cost-cutting needed to keep it profitable, or signs of renewed cash burn / restructuring charges, or serious regulatory/reimbursement setbacks.	GMED presentations at investor conferences; FDA & CMS sites for safety / reimbursement actions; Nevro-related 8-Ks.	Google Trends for “HF10 spinal cord stimulation”; your workforce data for Nevro salesforce cuts vs growth; clinical community forums discussing HF10 uptake.	Claims data for spinal cord stimulation implants; payor policy tracking services; device-specific procedure/utilization feeds.
Policy / reimbursement or macro capex shocks impacting spine & neuromod	Spine surgery and neuromod are sensitive to Medicare/insurer reimbursement and hospital capital budgets. Sudden policy or macro shifts can change the growth/margin outlook quickly.	Any CMS rule changes affecting spine or neuromod DRGs/CPTs; major hospital systems announcing capex freezes or surgery slowdowns; macro data pointing to renewed hospital financial stress.	Bullish: Neutral/benign CMS updates; commentary that hospital finances and capex are improving; more build-out of ASCs that adopt advanced spine tech. Bearish: Reimbursement cuts for spine or neuromod, high-profile hospital capex cuts, or macro shocks that delay elective/semi-elective surgeries.	CMS final rules & LCDs (usually Nov for major updates); large hospital system earnings calls; AHA / Kaufman Hall hospital margin reports.	Google Trends for “spine surgery cost”; public hospital financial dashboards; your workforce data on hospital hiring/furloughs.	Healthcare claims and reimbursement analytics (e.g., Clarivate, IQVIA, Syntellis); hospital margin/benchmarking data; macro “healthcare capex” alt-data feeds.

Key Reported Metrics3 rows

Metric	Why It Matters	Last Period
Nevro Revenue & EBITDA Margin	Determines whether the neuromodulation acquisition becomes a sustained growth and margin driver. Early integration success surprised the market—confirmation is critical.	Revenue: +4.9% QoQ (Nevro not disclosed YoY); EBITDA margin: 16.2%
Enabling Technologies Revenue (Robotics & Navigation)	The only soft spot last quarter. Hospitals shifting toward leases/pay-per-use stretched deal timing. A rebound (or stabilization) will signal pipeline conversion and capital discipline improvements.	−26.8% YoY
U.S. Spine Revenue Growth	Core indicator of Globus' competitive share gains, salesforce momentum, and implant pull-through from its robotics/navigation ecosystem. It is the most profitable part of the business and heavily influences total EBITDA.	'+9.6% YoY

Key Questions

Can U.S. Spine sustain high-single-digit (or better) growth as competitive rep hiring and implant pull-through continue?

Question 2: Will robotics/enabling-tech revenue stabilize or rebound after a sharp YoY decline, despite more leasing and slower hospital capital spending?
Question 3: Can Nevro show another quarter of margin and cash-flow improvement without hurting top-line momentum during integration?

Earnings Transcript SummaryTable

2025-12-01 · 2025 Q3 Earnings

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
1) Grow U.S. core spine faster than the market – keep a long streak of weekly growth going by aggressively recruiting experienced sales reps from competitors, putting more implant “sets” into hospitals, and using their robot/navigation ecosystem to pull through more implants per surgeon. 2) Fix and scale Nevro – turn the newly acquired chronic-pain nerve-stimulation business into a steady, cash-generating unit by cutting overlapping costs, improving manufacturing and supply chain, and then using its “electrical pulse” pain devices to go after more nerve-pain conditions over time. 3) Expand high-margin musculoskeletal platform and margins – keep pushing trauma and joint businesses toward “full-line” status, grow international spine into a 10–15% grower over time, and continue marching margins and free cash flow higher (via manufacturing insourcing, synergy capture, and disciplined CapEx) while funding R&D and share buybacks without taking on debt.	A decisive “beat and raise” quarter: core U.S. spine is accelerating, trauma is healthy, and Nevro is performing better and more profitably than feared, driving record earnings and free cash flow. Management raised full-year revenue and EPS guidance and emphasized durable growth, synergy execution, and a strong balance sheet with ongoing buybacks. The tone was confident and upbeat, with the main watch-outs being lumpier robot/capital sales and the need to keep executing on Nevro integration and international supply.	Total revenue: +18.4% YoY; Base business (ex-Nevro): +3.3%; Musculoskeletal solutions: +19.8%; Enabling technologies: −4.4% (robots already under pressure); U.S. sales: +20.3%; International sales: +11.0%; U.S. Spine: +5.7% (19 weeks of consecutive growth); Trauma: about +35% YoY. Overall, Q3 showed clear acceleration vs Q2 in total, musculoskeletal, U.S, international, and U.S. Spine, while enabling tech declines deepened and trauma growth normalized from a very strong Q2.	1) Why is U.S. Spine suddenly this strong and is it sustainable? – Mgmt said growth is broad-based across the spine portfolio, not just one product, backed by 32 weeks of consecutive growth, strong competitive rep hiring, robotic pull-through, and last year's product launches; they aim to be a high-single-digit, above-market grower in core spine. 2) What's going on with robots/enabling tech and the shift to leases? – Analysts worried about the −27% YoY enabling-tech revenue and the move toward operating leases and pay-per-use. Mgmt said the pipeline is still strong and they're not losing deals, but hospital capital budgets and broader reviews of all competing systems are stretching deal timing; they expect a higher mix of leases/rentals over time, but are willing to trade upfront revenue for placements that drive more implant and service revenue. 3) Nevro margin path and growth risk – Questions focused on how Nevro got to a 16.2% EBITDA margin so quickly, how much more cost they can remove, and whether cuts risk the top line. Mgmt said early gains came from cutting overlapping R&D and back-office SG&A, and that next steps are to lift Nevro gross margins and further trim SG&A while leaning harder into rep/surgeon conversions; importantly, Nevro is now free-cash-flow positive and expected to be EPS-accretive already in 2025, not just in year two as initially guided.	Total revenue: +22.9% YoY; Base business (ex-Nevro): +7.0%; Musculoskeletal solutions (spine/trauma/joints implants & related): +26.2%; Enabling technologies (robots, imaging, navigation): −26.8%; U.S. sales: +24.6%; International sales: +16.5%; U.S. Spine (core back/neck implant hardware): +9.6%; Trauma (plates/screws for fractures): +17.2%.